The Capital Region of Denmark

Medicine & Life Sciences

1. Denmark 100%
2. Cohort Studies 70%
3. Therapeutics 59%
4. Systematic Reviews 55%
5. Randomized Controlled Trials 54%
6. Population 53%
7. Mortality 50%
8. Child 43%
9. Neoplasms 42%
10. Confidence Intervals 41%
11. Meta-Analysis 40%
12. Type 2 Diabetes Mellitus 38%
13. Exercise 34%
14. Placebos 33%
15. Registries 31%
16. Incidence 30%
17. Biomarkers 29%
18. Type 1 Diabetes Mellitus 28%
19. Genes 26%
20. Guidelines 26%
21. Survival 26%
22. Glucose 25%
23. Pregnancy 25%
24. Quality of Life 24%
25. Prospective Studies 24%
26. Heart Failure 24%
27. Pain 23%
28. Odds Ratio 22%
29. Stroke 22%
30. Mutation 22%
31. Schizophrenia 22%
32. Health 22%
33. Breast Neoplasms 21%
34. HIV 21%
35. Brain 21%
36. Muscles 20%
37. Myocardial Infarction 20%
38. Safety 20%
39. Magnetic Resonance Imaging 19%
40. Rheumatoid Arthritis 19%
41. Infections 19%
42. Atrial Fibrillation 19%
43. Cardiovascular Diseases 19%
44. Migraine Disorders 19%
45. Insulin 19%
46. Asthma 19%
47. Pharmaceutical Preparations 19%
48. Observational Studies 18%
49. Serum 18%
50. Chronic Obstructive Pulmonary Disease 18%
51. Inflammation 18%
52. Wounds and Injuries 17%
53. Depression 17%
54. Multiple Sclerosis 17%
55. Lung 16%
56. Parturition 16%
57. Obesity 16%
58. Recurrence 16%
59. Cross-Sectional Studies 16%
60. Mothers 16%
61. Body Mass Index 16%
62. Blood Pressure 16%
63. Pediatrics 16%
64. Databases 16%
65. Bipolar Disorder 15%
66. Kidney 15%
67. Delivery of Health Care 15%
68. Skin 15%
69. Morbidity 15%
70. Multicenter Studies 15%
71. Proteins 15%
72. Hip 14%
73. Phenotype 14%
74. Out-of-Hospital Cardiac Arrest 14%
75. Comorbidity 13%
76. Clinical Trials 13%
77. Cerebrovascular Circulation 13%
78. Healthy Volunteers 13%
79. Hormones 13%
80. Smoking 13%
81. Hospitalization 13%
82. Genotype 13%
83. Prostatic Neoplasms 13%
84. Education 13%
85. Inflammatory Bowel Diseases 12%
86. Skeletal Muscle 12%
87. Single Nucleotide Polymorphism 12%
88. Genome-Wide Association Study 12%
89. Liver 12%
90. Colorectal Neoplasms 12%
91. Patient Reported Outcome Measures 12%
92. Hypersensitivity 12%
93. Headache 12%
94. Drug Therapy 12%
95. Ovarian Neoplasms 12%
96. Rehabilitation 12%
97. Positron-Emission Tomography 11%
98. T-Lymphocytes 11%
99. Elderly 11%
100. Glucagon-Like Peptide 1 11%